Table 3.
Showing variable designs of scFv targeting TRAIL receptors.
| Designed molecule name | Target | Main effects | Ref. |
|---|---|---|---|
| scFvCD19:sTRAIL | CD19 | 1. Absence of side effects | 153 |
| 2. Increased antitumor activity against: | |||
| A) Hematologic tumor cell lines and B-CLL primary cells in vitro | |||
| B) Tumor xenograft model (B-ALL) in vivo | |||
| scFvCD33:sTRAIL | CD33 | Increased antitumor activity against hematologic tumor cell lines and AML primary cells in vitro | 154 |
| scFvCD70:TRAILmutRs | CD70 | Increased bioactivity with cytotoxic targeting to hematologic and solid tumor cell lines in vitro | 155 |
| scFv:G28-TRAIL | CD40 | Bifunctional molecule that not only activates TRAIL pathway but also induces DC maturation leading to immune cells activation. This was tested in Fibrosarcoma cell lines in vitro |
156 |
| MSC.scFvCD20-sTRAIL | CD20 | Increased antitumor activity with no side effects against: | 157 |
| A) Hematologic tumor cell lines and normal primary cells in vitro | |||
| B) Tumor xenograft model158 in vivo |